Compare Gilead Sciences, Inc. (GILD) vs Kohl's Corporation (KSS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Kohl's Corporation — how do they compare? Gilead Sciences, Inc. trades at $133.6 (market cap $163.51B), while Kohl's Corporation trades at $18 (market cap $1.94B). The key difference: Gilead Sciences, Inc. is far larger — about 84.3× Kohl's Corporation's market cap, and Kohl's Corporation pays the higher dividend (2.92%). Which is the better fit depends on your goals.
| GILD | KSS | |
|---|---|---|
Market Cap | $163.51B | $1.94B |
Sector | Health | Consumer Cyclical |
52-Week High | $155.80 | $24.71 |
52-Week Low | $108.22 | $9.39 |
Enterprise Value | $178.05B | $8.04B |
Dividend Yield | 2.49% | 2.92% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Kohl's (KSS) trades at $16.42, down 0.79% on the day, as the stock shows mixed signals. Technically, the overall signal is bearish with key support at $16, while fundamentally, the company presents deep value with a P/E of 7.18 and P/B of 0.48, despite declining revenue and a thin 1.77% net margin. Recent Q1 2026 earnings beat expectations, and news highlights a focus on proprietary brands and a new COO appointment as part of a turnaround effort.
The outlook is a battle between deep value and operational challenges. The low valuation multiples and recent earnings beats present a potential opportunity for value investors, but significant risks remain from persistent revenue declines, weak profitability, and intense retail competition. Analyst sentiment is cautiously mixed with a $16.75 price target slightly above the current price.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Kohl's Corporation
Kohl's operates 1,165 department stores in 49 states that sell moderately priced private-label and national brand clothing, shoes, accessories, cosmetics, and home furnishings. Most of these stores are in strip centers. Kohl's also operates a large digital sales business. Women's apparel is Kohl's largest category, having generated 27% of its 2021 sales. The retailer, headquartered in Menomonee Falls, Wisconsin, opened its first department store in 1962.
Read more on KSS →
